2 results match your criteria: "Russian Federation Siberian State Medical University[Affiliation]"
Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB.
Clin Infect Dis
July 2016
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts Partners In Health, Boston, Massachusetts.
Background: We sought to determine whether treatment with a "long aggressive regimen" was associated with lower rates of relapse among patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russia.
Methods: We conducted a retrospective cohort study of adult patients that initiated MDR-TB treatment with individualized regimens between September 2000 and November 2004, and were successfully treated. Patients were classified as having received "aggressive regimens" if their intensive phase consisted of at least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for at least 6 months post culture conversion, and their continuation phase included at least 4 likely effective drugs.
Relationship between the expression of phosphorylated heat shock protein beta-1 with lymph node metastases of breast cancer.
Cancer Biomark
February 2016
Tomsk Cancer Research Institute, Tomsk, Russian Federation Siberian State Medical University, Tomsk, Russian Federation.
Background: Heat shock protein beta-1 (HspB1) is a chaperone of the sHsp (small heat shock protein). The common functions of sHsps are chaperone activity, inhibition of apoptosis, regulation of cell development, and cell differentiation, take part in signal transduction.
Objective: To study the intracellular localization of phosphorylated features and non-phosphorylated forms of HspB1 in primary breast cancer cells and to evaluate their relationship with regional lymphatic metastasis.